Citations

Showing 10 of 108094 citations.

Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines
Ku, Jennifer H , Henkle, Emily , Aksamit, Timothy R. , Winthrop, Kevin , BARKER, ALAN ROBERT , Brunton, Amanda E.

Mayo Clinic

Clinical Infectious Diseases | September 22, 2022 | Volume: 76 | Issue: 2 | Pages: 338-341

10.1093/cid/ciac788 | PMID 36134755 Get It

Abstract Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.
Peripheral artery disease and the risk of venous thromboembolism
Sykora, Daniel , Firth, Christine , Girardo, Marlene , Bhatt, Shubhang K. , Liedl, David , Wennberg, Paul W. , Shamoun, Fadi , Bhatt, Shubhang, Tseng, Andrew , Chamberlain, Alanna, Wennberg, Paul, Shamoun, Fadi Elias , Tseng, Andrew S. , Chamberlain, Alanna M.

Mayo Clinic

Vasa | September 22, 2022 | Volume: 51 | Issue: 6 | Pages: 365-371

10.1024/0301-1526/a001029 | PMID 36134738 Get It

Summary: Background: Peripheral artery disease (PAD) impacts 3–12% of patients worldwide and is characterized by endothelial dysfunction and inflammatory pathways which are also common to venous thromboembolism (VTE), but there is a paucity of evidence regarding VTE risk in PAD patients. We investigated whether PAD is an independent risk factor for VTE. Patients and methods: We reviewed medical records of patients undergoing ABI studies at Mayo Clinic from 01/1996-02/2020. We classified patients by ABI (low [<1.0], normal [1.0–1.4], or elevated [>1.4]), as well as by specific low ABI subgroup: severely reduced (ABI: 0.00–0.39), moderately reduced (0.40–0.69), mildly reduced (0.70–0.90), and borderline reduced (0.91–0.99). The primary outcome was incident VTE event (acute lower extremity deep vein thrombosis or pulmonary embolism) after ABI measurement. Multivariable Cox proportional regression was used to calculate hazard ratios (HR) with 95% confidence intervals (CI) after adjusting for age, sex, active smoking, cancer, previous VTE, thrombophilia, anticoagulation, and revascularization. Results: 39,834 unique patients (mean age 66.3±14.3 years, median follow-up 34 months) were identified. 2,305 VTE events occurred in patients without PAD (13.0%), 2,218 in low ABI patients (13.0%), and 751 in elevated ABI patients (14.8%). After risk factor adjustment, VTE risk was modestly increased for PAD overall (HR: 1.12, 95% CI [1.06, 1.18]), including low ABI (HR: 1.11, 95% CI [1.04, 1.18]) and elevated ABI groups (HR: 1.15, 95% CI [1.04, 1.26]), compared to patients without PAD. The greatest VTE risk was in severely low ABI patients (HR: 1.46, 95% CI [1.31, 1.64]). Conclusions: In a large longitudinal cohort, we present strong clinical evidence of PAD, with low and elevated ABI, as an independent VTE risk factor, with the highest risk seen in patients with severely low ABI. Continued research is required to further investigate this relationship and its intersection with functional performance status to optimize VTE risk reduction or anticoagulation strategies in the PAD population.
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
Sicotte, Hugues , Qin, Sisi , Dehm, Scott M. , Bhargava, Vipul , Gormley, Michael , Tan, Winston , Hillman, David W. , Li, Ying , Vedell, Peter T. , Carlson, Rachel E. , Bryce, Alan H. , Jimenez, Raphael E., Weinshilboum, Richard M. , Wang, Liewei , Kalari, Krishna R , Qin, Sisi , Dehm, Scott M , Bhargava, Vipul , Gormley, Michael , Tan, Winston , Sinnwell, Jason P , Hillman, David W , Li, Ying , Vedell, Peter T , Carlson, Rachel E , Bryce, Alan H , Jimenez, Raphael E , Weinshilboum, Richard M. , Kohli, Manish , Wang, Liewei , Kalari, Krishna R. , Sinnwell, Jason P. , Kohli, Manish

Mayo Clinic

Molecular Cancer Research | September 22, 2022 | Volume: 20 | Issue: 12 | Pages: 1739-1750

10.1158/1541-7786.mcr-22-0099 | PMID 36135372 Get It

Abstract We identified resistance mechanisms to abiraterone acetate/prednisone (AA/P) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study. We analyzed whole-exome sequencing (WES) and RNA-sequencing data from 83 patients with metastatic biopsies before (V1) and after 12 weeks of AA/P treatment (V2). Resistance was determined by time to treatment change (TTTC). At V2, 18 and 11 of 58 patients had either short-term (median 3.6 months; range 1.4–4.5) or long-term (median 29 months; range 23.5–41.7) responses, respectively. Nonresponders had low expression of TGFBR3 and increased activation of the Wnt pathway, cell cycle, upregulation of AR variants, both pre- and posttreatment, with further deletion of AR inhibitor CDK11B posttreatment. Deletion of androgen processing genes, HSD17B11, CYP19A1 were observed in nonresponders posttreatment. Genes involved in cell cycle, DNA repair, Wnt-signaling, and Aurora kinase pathways were differentially expressed between the responder and non-responder at V2. Activation of Wnt signaling in nonresponder and deactivation of MYC or its target genes in responders was detected via SCN loss, somatic mutations, and transcriptomics. Upregulation of genes in the AURKA pathway are consistent with the activation of MYC regulated genes in nonresponders. Several genes in the AKT1 axis had increased mutation rate in nonresponders. We also found evidence of resistance via PDCD1 overexpression in responders. Implications: Finally, we identified candidates drugs to reverse AA/P resistance: topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AURKB/TOP2A and/or PI3K_AKT_MTOR pathways.
AMPK: The key to ischemia‐reperfusion injury
Cai, Jie , Chen, Xinyue , Liu, Xingyu , Li, Zhangwang , Shi, Ao , Tang, Xiaoyi, Xia, Panpan, Zhang, Jing , Yu, Peng

Mayo Clinic

Journal of Cellular Physiology | September 22, 2022 | Volume: 237 | Issue: 11 | Pages: 4079-4096

10.1002/jcp.30875 | PMID 36134582 Get It

AbstractIschemia‐reperfusion injury (IRI) refers to a syndrome in which tissue damage is further aggravated and organ function further deteriorates when blood flow is restored after a period of tissue ischemia. Acute myocardial infarction, stress ulcer, pancreatitis, intestinal ischemia, intermittent claudication, acute tubular necrosis, postshock liver failure, and multisystem organ failure are all related to reperfusion injury. AMP‐activated protein kinase (AMPK) has been identified in multiple catabolic and anabolic signaling pathways. The functions of AMPK during health and diseases are intriguing but still need further research. Except for its conventional roles as an intracellular energy switch, emerging evidence reveals the critical role of AMPK in IRI as an energy‐sensing signal molecule by regulating metabolism, autophagy, oxidative stress, inflammation, and other progressions. At the same time, drugs based on AMPK for the treatment of IRI are constantly being researched and applied in clinics. In this review, we summarize the mechanisms underlying the effects of AMPK in IRI and describe the AMPK‐targeting drugs in treatment, hoping to increase the understanding of AMPK in IRI and provide new insights into future clinical treatment.
Migrating Into a Cell-Dense Tissue
Carmichael, Stephen W.

Mayo Clinic

Microscopy Today | September 22, 2022 | Volume: 30 | Issue: 5 | Pages: 8-9

10.1017/s1551929522001031 Get It

Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)
Shander, Aryeh , Corwin, Howard L., Meier, Jens , Bisbe, Elvira , Erhard, J., Faraoni, David , Farmer, Shannon L. , Hall, Tiffany , Hardy, Jean‐François, Hofmann, Axel , Lee, Cheuk‐Kwong, Leung, Tsin Wah, Ozawa, Sherri , Sathar, Jameela , Torres, Rosalio, Múñoz, Manuel , Auerbach, Michael , Blitz, Jeanna D. , Frank, Steven M. , Girelli, Domenico , Lee, Cheuk Kwong , Spahn, Donat R. , Warner, Matthew A.

Mayo Clinic

Annals of Surgery | September 22, 2022 | Volume: 277 | Issue: 4 | Pages: 581-590

10.1097/sla.0000000000005721 | PMID 36134567 Get It

Background: Perioperative anemia has been associated with increased risk of red blood cell transfusion and increased morbidity and mortality after surgery. The optimal approach to the diagnosis and management of perioperative anemia is not fully established. Objective: To develop consensus recommendations for anemia management in surgical patients. Methods: An international expert panel reviewed the current evidence and developed recommendations using modified RAND Delphi methodology. Results: The panel recommends that all patients except those undergoing minor procedures be screened for anemia before surgery. Appropriate therapy for anemia should be guided by an accurate diagnosis of the etiology. The need to proceed with surgery in some patients with anemia is expected to persist. However, early identification and effective treatment of anemia has the potential to reduce the risks associated with surgery and improve clinical outcomes. As with preoperative anemia, postoperative anemia should be treated in the perioperative period. Conclusions: Early identification and effective treatment of anemia has the potential to improve clinical outcomes in surgical patients.
Post-cardioversion Atrial Stunning -- Not to be Forgotten
Naqvi, Tasneem Z. , Kurt, Merve

Mayo Clinic

No container title available | September 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166383364.46595488/v1 Get It

We present a case of a 60 year old male who found to be in atrial fibrillation during routine evaluation. Anticoagulation was initiated for 36 hours and he was referred for TEE guided electrical cardioversion. There was no thrombus identified in the left atrial appendage, however the appendage was large and had a tongue like accessory lobe along with spontanous contrast on the left atrium and its appendage. TEE probe was not withdrawn, patient underwent successful cardioversion with 200 joules and developed a thrombus in the left atrial appendage immediately after cardioversion, which rapidly became more dense. There was an associated marked decrease in appendage velocities. Patient was hospitalized to initiate low molecular weight heparin. This case highlights the need for vigilance in patients with unknown duration of atrial fibrillation, who have received a short duration of anticoagulant therapy and who have adverse appendage anatomy as thrombus may develop immediately after cardioversion despite anticoagulation.
Facebook Intervention to Connect Alaska Native People With Resources and Support to Quit Smoking: CAN Quit Pilot Randomized Controlled Trial
Patten, Christi A. , Koller, Kathryn R. , Prochaska, Judith J. , Resnicow, Ken , Decker, Paul A. , Hughes, Christine A. , Merritt, Zoe T , McConnell, Clara R , Thomas, Timothy K. , Sinicrope, Pamela S. , Thomas, Timothy K , Young, Colleen , Patten, Christi , Koller, Kathryn , Decker, Paul A. , Huang, Ming

Mayo Clinic

Nicotine & Tobacco Research | September 21, 2022 | Volume: 25 | Issue: 4 | Pages: 803-813

10.1093/ntr/ntac221 | PMID 36130170 Get It

AbstractIntroductionThere is some evidence that social media interventions can promote smoking cessation. This randomized controlled pilot study is the first to evaluate the feasibility and potential efficacy of a Facebook smoking cessation intervention among Alaska Native (AN) adults.Aims and MethodsRecruitment and data collection occurred from December 2019 to March 2021. Participants were recruited statewide in Alaska using Facebook advertisements with a targeted sample of 60 enrolled. Participants were stratified by gender, age, and rural or urban residence and randomly assigned to receive referral resources on evidence-based cessation treatments (EBCTs) (control, n = 30) or these resources plus a 3-month, closed (private), culturally tailored, Facebook group (intervention, n = 31) that connected participants to EBCT resources and was moderated by two Alaska Native Trained Tobacco Specialists. Assessments were conducted online post-randomization at 1, 3, and 6 months. Outcomes were feasibility (recruitment, retention, and intervention engagement), self-reported use of EBCTs, and biochemically confirmed seven-day point-prevalence smoking abstinence.ResultsOf intervention participants, 90% engaged (eg posted, commented) more than once. Study retention was 57% at 6 months (no group differences). The proportion utilizing EBCTs was about double for intervention compared with the control group participants at 3 and 6 months. Smoking abstinence was higher for intervention than control participants at 3 months (6.5% vs. 0%, p = .16) but comparable at 6 months (6.4% vs. 6.7%, p = .97).ConclusionsWhile additional research is needed to promote long-term cessation, this pilot trial supports recruitment feasibility during the Coronavirus Disease 2019 (COVID-19) pandemic, consumer uptake, and a signal for intervention efficacy on the uptake of cessation treatment and short-term smoking abstinence.ImplicationsThis study is the first evaluation of a social media intervention for smoking cessation among Indigenous people. We learned that statewide Facebook recruitment of AN adults who smoke was feasible and there was a signal for the efficacy of a Facebook intervention on the uptake of EBCT and short-term (3 months) biochemically verified smoking abstinence. Clinically, social media platforms may complement current care models by connecting AN individuals and others living in hard-to-reach communities to cessation treatment resources.
Single Versus Double Anastomosis Duodenal Switch in the Management of Obesity: A Meta-analysis and Systematic Review
Nakanishi, Hayato , Vahibe, Ahmet , Galvani, Carlos , Pullatt, Rana , Davis, Steven Scott, Clapp, Benjamin , Ghanem, Omar M. , Matar, Reem , Dayyeh, Barham K. Abu

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | September 21, 2022 | Volume: 32 | Issue: 5 | Pages: 595-605

10.1097/sle.0000000000001102 | PMID 36130714 Get It

Background: Biliopancreatic diversion with duodenal switch (BPD-DS) is an effective yet technically challenging bariatric surgery with many complications. Alternatively, single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) was recently introduced as a simplified bariatric procedure. This meta-analysis aimed to assess the safety and efficacy of SADI-S compared with BPD-DS in the management of patients with obesity. Methods: Cochrane, Embase, PubMed, Scopus, and Web of Science were searched for articles from their inception to May 2022 by 2 independent reviewers using the Preferred Reporting Items for Systematic Reviews and Meta-analysis system. The review was registered prospectively with PROSPERO (CRD42022333521). Results: From 123 studies screened, 6 studies met the eligibility criteria, with a total of 1847 patients with obesity undergoing either SADI-S (n=818) or BPD-DS (n=1029). Preoperative body mass index was similar between the 2 groups, and the BPD-DS group had a greater % excess body mass index loss (EBMIL) (MD=−10.16%, 95% confidence interval: −11.80, −8.51, I2=0%) at 2 years compared with the SADI-S group. There was no difference observed in preoperative comorbidities and remission, including diabetes, hypertension, and dyslipidemia between SADI-S and BPD-DS cohorts. Compared with BPD-DS, SADI-S had shorter hospital stays (MD=−1.36 d, 95% CI: −2.39, −0.33, I2=86%), and fewer long-term (>30 d) complications (OR=0.56, 95% CI: 0.42, 0.74, I2=20%). Conversely, among nutritional deficiency outcomes, the SADI-S group had few patients with abnormal vitamin D (OR=0.51, 95% CI: 0.36, 0.72, I2=0%) values than the BPD-DS group. Conclusions: SADI-S has shown to be a possible alternative treatment option to BPD-DS in managing patients with obesity. Despite the promising results, further randomized controlled studies with more extended follow-up periods are necessary to ascertain the safety and efficacy of the treatment.
On the Dielectric Characterization of Biological Samples for Microwave Imaging Reconstruction
Samaddar, Poulami , Gaddam, Sunil , Khan, Muhammad Rehan , Mitra, Dipankar , Arunachalam, S P , Roy, Sayan , Arunachalam, Shivaram P.

Mayo Clinic

2022 IEEE International Symposium on Antennas and Propagation and USNC-URSI Radio Science Meeting (AP-S/URSI) | September 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: 870-871

10.1109/ap-s/usnc-ursi47032.2022.9887074 Get It